Open AccessApixaban used for the management of heparin‐induced thrombocytopenia in a 72‐year‐old woman with lung cancer
Author(s) -
Larsen Pia Bükmann,
Jørgensen Maja,
FriisHansen Lennart,
Ingeberg Steen
Publication year - 2015
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.411
Subject(s) - medicine , apixaban , heparin induced thrombocytopenia , heparin , lung cancer , adverse effect , thrombosis , intensive care medicine , surgery , warfarin , rivaroxaban , atrial fibrillation
Key Clinical Message Heparin‐induced thrombocytopenia ( HIT ) is a serious adverse reaction to heparin treatment with a high risk of thrombosis. Heparin must be discontinued immediately and replaced with alternative anticoagulants that do not interact with HIT antibodies. In this case, a lung cancer patient, diagnosed with HIT was successfully treated with apixaban.